SAGE recommends introduction of dengue vaccine in geographic set-tings with high endemicity

ABSTRACT

The Strategic Advisory Group of Experts [SAGE] on immunization recently reviewed the evidence generated from two large Phase 3 clinical trials, one conducted in Asia and the other in Latin America. On the basis of currently available evidence, SAGE recommended that the countries may consider introduction of dengue vaccine [CYD-TDV] only in in geographic settings with high endemicity [seroprevalence is greater than 70% or more in targeted age group or other suitable epidemiologic marker]